Grasp the latest information from Olin and understand the new trends in the industry.
On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in
Vaccines have played an irreplaceable role from vaccinia vaccination against smallpox in the 18th century in England to the national prevention and control of pandemic diseases typified by COVID-19 in the 21st century.
On July 6, 2022, Chengdu XENOMIX Biotechnology Co., Ltd. (hereinafter referred to as “XENOMIX”), a wholly-owned subsidiary of Chengdu Olymvax Biopharmaceuticals Inc., and Lanzhou Bailing Bio-Tech Company Limited (hereinafter referred to as “Bailing Bio-Tech”) held a signing ceremony for the cell-based influenza vaccine project in Chengdu.
On June 6, 2022, the Phase III Clinical Trial Kick-off Meeting of Recombinant Staphylococcus Aureus Vaccine (RSAV) (hereinafter referred to as “Staphylococcus Aureus Vaccine”), jointly developed by Chengdu Olymvax Biopharmaceuticals Inc.
On May 8, 2022, the “OLYMVAX Cup” the 8th CMC College Student’s “Internet +” Innovation and Entrepreneurship Competition, jointly organized by Chengdu Olymvax Biopharmaceuticals Inc.
On the morning of March 16, 2022, Ms. Adelle Neary, Consul General of Australian Consulate General in Chengdu, and her delegation visited OLYMVAX and discussed the future cooperation between the two parties.